GlassScriptPhysician profile
Katelyn S White
NPI 1730661521
$4,111.67
in general payments reported to CMS, 2019-2025
32 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $125 · 2023: $199 · 2024: $600 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.77 |
| Education | $177.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,152.32 | 2021-2025 | Enhertu, Tagrisso |
| Janssen Biotech, INC. | $753.98 | 2023-2025 | Rybrevant, Erleada, Akeega |
| Incyte Corporation | $359.72 | 2021-2025 | Zynyz, Jakafi, Jakafi |
| Amgen INC. | $333.37 | 2021-2025 | Kyprolis, Imdelltra (Amg757) |
| Takeda Pharmaceuticals U.S.A., INC. | $166.55 | 2025 | Hyqvia, Ninlaro |
| Glaxosmithkline, LLC. | $131.19 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2025 | |
| Pfizer INC. | $124.98 | 2025 | |
| Genzyme Corporation | $121.82 | 2025 | |
| Astellas Pharma US INC | $115.48 | 2025 | Padcev |
| Gilead Sciences, INC. | $110.74 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $66.52 | 2024-2025 | Iqirvo, Onivyde, Somatuline Depot |
| Merck Sharp & Dohme LLC | $62.20 | 2025 | Keytruda, Welireg, Reblozyl |
| Genentech USA, INC. | $48.00 | 2025 | Polivy |
| Daiichi Sankyo INC. | $46.48 | 2025 | Enhertu, Datroway |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $45.88 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $39.77 | 2025 | Libtayo |
| Sobi, INC | $39.48 | 2025 | |
| Adaptive Biotechnologies Corporation | $28.61 | 2025 | Clonoseq |
| Abbvie INC. | $27.76 | 2025 | |
| Menarini Silicon Biosystems, INC. | $21.78 | 2025 | |
| Lilly USA, LLC | $20.01 | 2025 | Jaypirca, Verzenio, Retevmo |
| Emd Serono, INC. | $19.69 | 2025 | |
| Array Biopharma INC | $19.17 | 2025 | Tukysa, Braftovi, Mektovi |
| Pharmaessentia USA Corporation | $17.92 | 2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.55 | 2025 | |
| Beone Medicines USA, INC. | $17.37 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $17.18 | 2025 | |
| Eisai INC. | $17.08 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.34 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.94 | 2025 | Ultomiris |
| Stemline Therapeutics INC. | $13.80 | 2025 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.